Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $215.88

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given an average recommendation of “Moderate Buy” by the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $215.88.

A number of equities research analysts have weighed in on ALNY shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. raised their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research report on Thursday, February 1st.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Mediolanum International Funds Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $5,953,000. Central Pacific Bank Trust Division purchased a new stake in Alnylam Pharmaceuticals during the first quarter worth about $161,000. Daiwa Securities Group Inc. raised its position in Alnylam Pharmaceuticals by 1.1% in the first quarter. Daiwa Securities Group Inc. now owns 10,921 shares of the biopharmaceutical company’s stock worth $1,632,000 after acquiring an additional 116 shares during the period. Nordea Investment Management AB boosted its stake in Alnylam Pharmaceuticals by 3.3% in the first quarter. Nordea Investment Management AB now owns 8,980 shares of the biopharmaceutical company’s stock valued at $1,365,000 after acquiring an additional 290 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its position in shares of Alnylam Pharmaceuticals by 7.7% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,849 shares of the biopharmaceutical company’s stock valued at $575,000 after acquiring an additional 274 shares during the period. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $152.33 on Tuesday. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $218.88. The company’s 50-day simple moving average is $149.65 and its 200 day simple moving average is $165.14. The company has a market capitalization of $19.19 billion, a PE ratio of -56.84 and a beta of 0.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The company’s quarterly revenue was up 54.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.40) EPS. On average, analysts forecast that Alnylam Pharmaceuticals will post -4.46 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.